Sanofi shares among the biggest decliners in the CAC 40 despite European green light for VaxRabeo
The pharmaceutical group falls sharply while the Paris index rises. The stock gives up part of its recent strong rebound, after a series of highs. The European authorisation of a new vaccine, announced this Thursday, is not enough to reverse the trend.
A decline that places Sanofi at the bottom of the Paris index
Sanofi shares fall 2.27% to €84.29 intraday, while the CAC 40 gains 0.34%. Only Capgemini performs worse in the index, placing the stock among the biggest decliners of the CAC 40.
The drop follows a month of strong recovery (+17.17%), so the price remains well above its 20-day moving average (€82.43, a gap of 2.26%). The RSI at 60 remains neutral.
Over the week, the stock loses 2.68%, a modest correction given its monthly rebound, in a market where Wall Street closed mixed the previous day, with the Dow Jones falling by about 1.1%.
A rabies vaccine authorised in Europe, with no visible effect on the share price
The European Commission has granted VaxRabeo its first marketing authorisation, according to the company's announcement on 19 November. The vaccine covers pre-exposure and post-exposure prophylaxis against rabies, for all age groups. The decision follows the positive opinion issued on 17 September by the Committee for Medicinal Products for Human Use of the European Medicines Agency.
According to the consensus of the analysts surveyed, the stock trades at about 9.5 times earnings for the current fiscal year. The share price crossed €87.98 on 16 November, a 250-session high, before pulling back. Resistance at €88.32 remains the nearest technical level above the current price.